Publicaciones en colaboración con investigadores/as de University of Bologna (71)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial

    The Lancet Gastroenterology and Hepatology, Vol. 9, Núm. 9, pp. 802-810

  3. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

  4. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

  5. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  6. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

  7. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome

    JHEP Reports, Vol. 6, Núm. 7

  8. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

  9. Should We Use Rifampicin in Periprosthetic Joint Infections Caused by Staphylococci When the Implant Has Been Exchanged? A Multicenter Observational Cohort Study

    Open Forum Infectious Diseases

  10. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results

    EJHAEM, Vol. 4, Núm. 4, pp. 1117-1131

  2. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours

    The Lancet Haematology, Vol. 10, Núm. 5, pp. e367-e381

  3. If You're Not Confused, You're Not Paying Attention: Ochrobactrum Is Not Brucella

    Journal of clinical microbiology, Vol. 61, Núm. 8, pp. e0043823

  4. Model to predict major complications following liver resection for HCC in patients with metabolic syndrome

    Hepatology, Vol. 77, Núm. 5, pp. 1527-1539

  5. Reference standards for gene fusion molecular assays on cytological samples: an international validation study

    Journal of clinical pathology, Vol. 76, Núm. 1, pp. 47-52

2022

  1. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750

  2. SUCCOR cone study: conization before radical hysterectomy

    International Journal of Gynecological Cancer, Vol. 32, Núm. 2, pp. 117-124

  3. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Blood, Vol. 139, Núm. 4, pp. 492-501

  4. TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: An international performance evaluation study

    Journal of Clinical Pathology, Vol. 75, Núm. 6, pp. 416-421

  5. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116